Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on AZD9291. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Novel catalytic hydrogenation route for AZD9291 intermediate offers high purity and scalable production for global pharmaceutical supply chains.
Patent CN106366072B details a high-yield convergent synthesis route for Osimertinib, offering cost reduction and supply chain reliability for pharmaceutical intermediates manufacturing.
Patent CN109134435A details a high-yield Osimertinib synthesis using cobalt catalysis. This method offers significant cost reduction and supply chain reliability for pharmaceutical intermediate manufacturing.
Patent CN104817541A reveals a high-yield synthetic route for AZD9291 intermediates. This report analyzes cost reduction in pharmaceutical manufacturing and supply chain reliability for global buyers.
Advanced preparation method for Oxitinib Mesylate intermediates via anhydrous catalysis. Delivers high purity, reduced genotoxic impurities, and scalable manufacturing for global supply chains.
Patent CN107935997A reveals a cost-effective Osimertinib route avoiding expensive chloropyrimidine. Enhance supply chain reliability with scalable manufacturing.
Patent CN106366022B reveals high-yield AZD9291 intermediate synthesis. Offers cost reduction in API manufacturing and supply chain reliability for global buyers.
Novel patent CN106397407B details high-yield AZD9291 derivative synthesis offering significant supply chain stability and cost reduction for pharmaceutical manufacturing.
Discover how advanced cuprous bromide activation and palladium-catalyzed hydrogenation reduce solid waste by 90% while achieving 99.8% purity and 72% yield for AZD9291 production.